SoluLinK, Inc. Awarded Phase I SBIR Contract to Develop a Multiplex Screen for the Rapid Detection of Breast Cancer

Published: Sep 15, 2011

San Diego, California — September 24, 2010. Solulink, Inc., a leading innovator of state-of- the-art conjugation reagents, easy-to-use linking kits, and conjugation services for the life science research, diagnostics, and pharmaceutical markets, today announced it has been awarded approximately $150,000 for a National Cancer Institute (NCI) SBIR Contract to develop a multiplex screen for simultaneous detection of multiple breast cancer markers. The grant entitled, “Universal Reagent Sets for Sensitive and Specific Multiplexed Immunofluorescent Cancer Diagnostics” proposes to develop an immunohistochemistry-based multiplex assay to detect multiple breast cancer biomarkers in a single tissue sample. The assay will be developed in association with Drs. Stephen Kron, Professor, Dept. Molecular Genetics and Cell Biology and Anthony Montag, Professor of Pathology and Surgery, at the University of Chicago. David Schwartz, Ph.D., Solulink’s Chief Science Officer and Principal Investigator for the project stated, “We are pleased that SBIR has awarded us the opportunity to apply our state of the art protein multiplexing platform technology to this important goal. With this grant, we propose to use our proprietary technology in combination with nanotechnology, bioorganic chemistry, immunochemistry, immunology and available instrumentation to develop an assay that provides more rapid and more complete diagnostic information, thereby enabling oncologists to make more informed decisions. We also are excited about continuing our collaboration with the University of Chicago in exploiting our technology in multiple diagnostic platforms”

The Small Business Innovation Research Program (SBIR) works to ensure that the nation’s small, high-tech, innovative businesses act as a significant part of the federal government’s research and development projects. In reviewing grant applications, the SBIR seeks unique research projects that are of high scientific caliber and are relevant to public health needs. SBIR Grant number: PH3 2010-1 NCI Topic 274

About Solulink

Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces including beads, chips, and slides. Solulink has developed several lines of products that incorporate its technology including streptavidin magnetic and agarose beads that have the highest binging capacity on the market, ChromaLink Biotin with a built in quantification feature, antibody labeling kits, oligo and peptide synthesis reagents. Solulink markets its products both directly and through distributors and licensing partners worldwide. Solulink is a privately held company located in San Diego, California. For more information, please visit


Steve DeGraw

Solulink, Incorporated

9853 Pacific Heights Blvd. Suite H,

San Diego, California 92121

T 858.625.0670

F 858.625.0770

Back to news